CDC Reports Poor Flu Vaccine Effectiveness for Current Season

The 2025-2026 flu season has been one for the record books — and not in a good way. On March 13, the Centers for Disease Control and Prevention published interim vaccine effectiveness estimates confirming what emergency rooms across the country had been signaling for months: this year's flu shots offered some of the weakest protection in over a decade [1][2].

The culprit is a mutant strain of influenza A(H3N2) called subclade K that emerged just months after scientists had already locked in the vaccine formula for the season. But the biological bad luck of viral evolution is only part of the story. The poor vaccine performance arrived against a backdrop of declining vaccination rates, controversial Trump administration changes to childhood immunization guidelines, and deep cuts to the public health workforce responsible for tracking and responding to outbreaks.

The result: at least 27 million Americans sickened, 350,000 hospitalized, and 22,000 dead from influenza between October 2025 and the end of February 2026 — with the season still not fully over [2][11].

The Numbers

The CDC's Morbidity and Mortality Weekly Report, published March 13, laid out the grim arithmetic. Among adults 18 and older, this season's vaccine was just 22-34% effective at preventing outpatient medical visits for flu and 30% effective against hospitalization. Among children and adolescents, the numbers were marginally better — 38-41% effectiveness against outpatient illness and 41% against hospitalization [1].

For context, flu vaccines are generally considered to perform "acceptably" in the 40-60% range [5]. The current season's overall effectiveness of roughly 29% places it alongside the notorious 2014-15 season (19%) and the 2018-19 season (29%) as one of the worst-performing vaccine years since systematic tracking began in 2004 [5].

Source: CDC / Past Seasons' Vaccine Effectiveness Estimates

Data as of Mar 13, 2026CSV

The disparity between virus types tells a revealing story. Against influenza B — a less common but still circulating strain — the vaccine performed respectably, with effectiveness ranging from 45-71% in children and 63% in adults. But against the dominant H3N2 subclade K, which accounted for roughly 90% of all flu cases this season, adult protection plunged as low as 11-20% in some measurement networks [1][6][10].

Source: CDC MMWR Vol. 75, No. 9

Data as of Mar 13, 2026CSV

Dr. William Schaffner, a vaccine expert at Vanderbilt University, told reporters that despite the disappointing numbers, "the winter respiratory virus season is slowly coming to a close, and we're all very grateful" [2]. He emphasized that even partial protection reduces the severity and duration of illness — cold comfort for the families of the 22,000 Americans who didn't survive.

The Rise of Subclade K

The story of how this season went wrong begins in a virology lab, with a calendar problem that haunts flu vaccine production every year.

Each February, the World Health Organization convenes a panel of experts to select which influenza strains should be included in the next season's vaccines for the Northern Hemisphere. Manufacturers then spend approximately six months growing the virus in fertilized chicken eggs, purifying it, and mass-producing hundreds of millions of doses [4][9].

Subclade K was first detected in New York in June 2025 — four months after the WHO had already made its strain selections for the 2025-2026 season [4][6]. The variant carried seven key mutations in its hemagglutinin protein, including T135K and S144N substitutions that altered the virus's surface just enough to partially evade vaccine-induced antibodies [6][13].

"It's an inconvenient convergence of timing and viral evolution," noted Florian Krammer, a virologist at Mount Sinai's Icahn School of Medicine [4]. By the time the Northern Hemisphere's flu season ramped up in October, subclade K had become dominant worldwide — spreading through Japan, Hong Kong, the United Kingdom, Canada, and Australia before sweeping through the United States [6][10].

Laboratory studies quantified the damage. Research published by England's public health authorities found a greater than 32-fold reduction in antibody reactivity when testing ferret antisera raised against the egg-propagated vaccine strain against subclade K viruses [13]. The problem was compounded by a well-known weakness of egg-based vaccine production: when flu viruses are grown in chicken eggs, they acquire additional mutations — a phenomenon called "egg adaptation" — that can further reduce the match between the vaccine strain and what's actually circulating [13].

Andrew Pekosz, a virologist at Johns Hopkins, described the situation succinctly: subclade K "may allow it to evade some but not all of the influenza-vaccine-induced protection" [6]. The result was what scientists call a "double mismatch" — antigenic drift in the virus itself, amplified by egg adaptation artifacts in the manufacturing process.

A Policy Storm During a Pandemic Season

The biological challenges of subclade K collided with a politically charged public health landscape. On January 5, 2026, the CDC — acting on a presidential directive from December 2025 — slashed the number of universally recommended childhood vaccinations from 17 to 11 [7][8]. Among the immunizations dropped from universal recommendation was the annual flu shot.

Under the new policy, childhood flu vaccination was reclassified as a "shared clinical decision-making" matter between parents and physicians — a category that, in practice, eliminates the infrastructure for school-based mass vaccination clinics that had been a primary delivery mechanism for childhood flu shots [7].

The timing stunned pediatricians. "Doing that in the middle of a serious influenza season is irresponsible," said Dr. David Higgins, a University of Colorado pediatrician [7]. Doctor visits for flu-like illness had already reached their highest level in nearly 30 years according to CDC data, and pediatric flu deaths were mounting [7][10].

Among the children who died from flu this season with known vaccination status, approximately 85-90% were unvaccinated [2][11]. Acting CDC Director Jim O'Neill, defending the policy change, questioned whether this season was truly more severe than the previous one and challenged the established benefits of childhood flu vaccination — positions that put him at odds with decades of scientific consensus [7].

The broader context matters. HHS Secretary Robert F. Kennedy Jr. had already moved in spring 2025 to eliminate routine COVID-19 shot recommendations for healthy children and pregnant women [7]. The childhood vaccination schedule overhaul followed a December 2025 presidential memorandum directing the CDC to review its immunization schedule against international benchmarks — though critics noted the process bypassed the usual public comment period and external expert review [8].

Childhood flu vaccination coverage, which had already been declining since the 2019-2020 season, dropped further this year to approximately 48% among those aged 6 months to 17 years, down from 50.2% the prior season and 55.5% two seasons earlier [1][10]. Geographic disparities were stark, with Southeastern and Western states showing coverage as low as 16-37% [10].

The Surveillance Gap

Compounding these challenges, the public health infrastructure responsible for tracking flu and responding to outbreaks has been under sustained pressure. Proposed CDC budget cuts would eliminate approximately 42,000 public health jobs nationwide, and the broader HHS workforce has already shrunk from roughly 82,000 to 62,000 — a 25% reduction [14].

The University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) highlighted the irony in a prescient pre-season analysis: scientists were heading into the 2025-2026 season facing both a known vaccine mismatch and an "absent CDC" with diminished capacity to monitor and respond [14].

Real-time disease surveillance — including case tracking, wastewater monitoring, and the vaccine effectiveness networks that produced the March 13 MMWR report — depends on a funded, staffed public health apparatus. Each reduction in that capacity means slower detection of emerging threats, less granular data on vaccine performance, and weaker early warning systems for the next subclade K-like surprise.

Source: GDELT Project

Data as of Mar 15, 2026CSV

What Comes Next: Fixing the Match

The WHO moved quickly. On February 27, 2026, the organization announced its strain recommendations for the 2026-2027 Northern Hemisphere flu season, explicitly targeting subclade K by selecting A/Darwin/1454/2025 as the new H3N2 reference virus for egg-based vaccines [9]. An FDA advisory committee endorsed the recommendations this week [12].

But the deeper question is whether the manufacturing system itself needs an overhaul. The six-month production timeline for egg-based vaccines — the same basic technology used since the 1940s — is the structural reason subclade K caught the world off guard. A virus that emerges in June simply cannot be incorporated into vaccines that are already being manufactured.

mRNA technology offers a potential escape from this trap. Moderna's mRNA influenza vaccine candidate, mRNA-1010, demonstrated superior efficacy in a Phase 3 trial of over 40,000 adults compared to standard licensed vaccines, and the FDA is expected to make a regulatory decision by mid-2026 [15]. The European Medicines Agency has already recommended authorization for Moderna's combination COVID-influenza mRNA vaccine for adults 50 and older [15].

mRNA platforms can be updated in weeks rather than months, potentially allowing manufacturers to respond to late-emerging variants like subclade K — a capability that could transform flu vaccination from its current annual gamble into something far more responsive. As of early 2026, 46 next-generation influenza vaccine candidates are in clinical development worldwide, with the WHO calling for vaccines that provide "broader and longer-lasting protection beyond a single flu season" [15].

The Broader Lesson

The 2025-2026 flu season exposes a paradox at the heart of American public health. The nation possesses some of the world's most sophisticated viral surveillance and vaccine development infrastructure, yet it remains trapped in a manufacturing paradigm that cannot keep pace with viral evolution — and is simultaneously dismantling the public health workforce that makes the system function at all.

Even at 29% effectiveness, the flu vaccine prevented illness, hospitalization, and death in millions of Americans this season. The prior season's vaccine, which performed at 56% effectiveness, prevented an estimated 5 million medical visits, 180,000 hospitalizations, and 12,000 deaths [1][5]. The gap between those numbers and this season's represents real human cost — not from a failure of science, but from a failure of timing, infrastructure, and political will.

The flu kills an average of 20,000-50,000 Americans in a typical season. It is not exotic, not novel, and not surprising. Yet year after year, the United States approaches it with a production system designed for the mid-20th century, vaccination campaigns that reach fewer than half the population, and a public health apparatus that is now being actively hollowed out. Subclade K was not the disease. It was the symptom.